SPOTLIGHT -
Cognitive Issues in Schizophrenia Remain a Challenge
How does John Kane, MD, address issues of cognition in schizophrenia?
Watch
Psychiatrists as Shakepeare's Fools
How can psychiatry avoid foolishness and be more like Shakespeare's fools?
Reset the Clock on Schizophrenia: SPG302, A Regenerative Treatment
SPG302, a regenerative treatment for schizophrenia, could reset the clock on the brain.
A Welcome Action: Removal of the REMS Requirement for Clozapine
John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.
Behind the Steering Wheel of Your Brain: Residual Negative and Cognitive Symptoms in Schizophrenia
Treatments that target negative and cognitive symptoms of schizophrenia could put patients in better control of their life.
LB-102: A New, Novel Drug for Schizophrenia
John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.
SPG302: A Synaptic Regenerative Treatment Option for Schizophrenia
A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.
LB-102 for the Treatment of Acutely Exacerbated Schizophrenia: Insights From the Principal Investigator
In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.
Celebrating World Bipolar Day 2025: Best Practices in Treating Bipolar Disorder
In honor of World Bipolar Day, our Mood Disorders Section Editor shares his favorite clinical pearls for treating bipolar disorder.
As Capitalism Gasps for Breath I Watch the Knicks Game
"Was this what Rome felt like toward the end? When the colosseums filled with gladiators stirred the masses into a frenzy."
Get Ready for Psyched Perspectives
Get ready for our new video series, "Psyched Perspectives"!
Psychiatric Times: An Essential, Practical Publication for Clinicians
After 40 years, Psychiatric Times is still your go-to resource for all things psychiatry. Just ask our Mood Disorders Section Editor.
The Role of Memory in Social Conflicts
How can we prevent the transmission of intergenerational trauma, which persists?
Removal of the REMS Requirement for Clozapine: Appropriate Monitoring Still Crucial
While the removal of the REMS requirement can be liberating, appropriate monitoring for patients with schizophrenia is still of the utmost importance.
Exciting Agents in the 2025 Mood Disorders Treatment Pipeline
Our Mood Disorders Section Editor shares what treatments in the pipeline he is most excited about, including kappa opioid receptor antagonists.
Re-Affirming Evidence-Based Psychiatric Care: A Joint Statement on Psychotropic Medication Safety
Joseph Goldberg, MD, discusses the recent joint statement on evidence-based medicine and psychotropic safety.
Expansion of the Glutamaterigc Story: Clinical Trial Successes and Failures in the Mood Disorders Space
Our Mood Disorders Section Editor shares his thoughts on this year's biggest clinical trial successes and failures.
The FDA Removal of the Clozapine REMS Requirement: An Expert Perspective
The FDA decision to remove the clozapine REMs requirement has left many questions. Chelsie Monroe, MSN, APN, PMHNP-BC, sheds some light on it.
John J. Miller, MD, Responds to Statement on Psychotropic Medication Concerns
Psychiatric Times Editor in Chief John J. Miller, MD, shares thoughts on psychiatry's response to the recent executive order.
"Leave Nothing Untouched": Pervasive Challenges in the Neuropsychiatric Space
What are the most pressing issues facing psychiatry? Gustavo Alva, MD, FAPA, shares his thoughts.
"Good Bones"
"Any decent realtor, walking you through a real shithole, chirps on about good bones: This place could be beautiful, right? You could make this place beautiful."
A Renaissance for Schizophrenia Treatment
Chelsea Monroe, MSN, APN, PMHNP-BC, discusses the current renaissance in treating schizophrenia.
A Multitude of Advancements Over the Past 40 Years
Celebrate our 40th anniversary with Gustavo Alva, MD, FAPA, our Mood Disorders Section Editor.
What Does the 5th Year Anniversary of COVID-19 Mean to You?
Let's process our trauma, grief, and healing from COVID-19.
"The Killer"
"I stood by her side, stunned when her breathing stopped..."
Digital Therapy Rejoyn Utilizes Neuroplasticity in Treating Depression
Rejoyn, a new app being prescribed as a depression treatment, is an emotional face memory task designed to correct abnormal neural circuits.
Marching Through Religious Holidays
Spring is full of religious holidays, each with potential psychosocial meaning...
Innovation and Failure in Developing New Psychiatric Treatments
Dennis S. Charney, MD, discussed the importance of trying and risking failure when studying new potential treatments, as well as the future of treating depression.
The Revolutionary Discovery of Ketamine as an Antidepressant
Dennis S. Charney, MD, discussed the discovery of ketamine as a rapid-acting treatment for depression, its journey from skepticism to FDA approval, and its impact on mental health care.
Chapter 4: Conclusion and Key Takeaways
